Verapamil (Calan, Verelan, Calan SR, Isoptin) Considerations for Use*

US/FDA Approved Indication: Heart Rate Control for Atrial Fibrillation

Mechanism of Action	Blocks calcium-dependent contractions in cardiac and peripheral smooth muscle
	leading to vasodilation; slows cardiac conduction through SA node
Dosing [†]	Acute setting: 0.075 to 0.15 mg/kg (average 5 to 10 mg) IV over 2 minutes; 2 nd dose of 10 mg IV may be given 15-30 minutes later if needed
	Non-acute setting or maintenance: 120 to 480 mg daily, slow-release/extended release available and preferred
	<u>Elderly:</u> In general, use lower adult dosage and administer over at least 3 minutes; adjust dosage based on clinical response
	Hepatic Impairment: Use with caution; if possible reduce initial dosage to about 33% of the usual starting dosage and adjust based on clinical goals
	Renal Impairment: Use with caution; no dosage adjustment needed
Contraindications	severe LV dysfunction
	• hypotension (SBP < 90)
	cardiogenic shock
	sick sinus syndrome without pacemaker
	 2nd or 3rd degree AV block without pacemaker
	 A-Fib/flutter conducted via accessory pathway (ie, Wolff-Parkinson-White)
Major Side Effects	hypotension, heart block, HF
Dosage forms and Strengths	<u>PO:</u>
	40 mg, 80 mg, 120 mg immediate-release tablets (Calan®)
	120 mg, 180 mg, 240 mg sustained-release tablets (Isoptin® SR)
	120 mg, 180 mg, 240 mg, 360 mg sustained-release capsules (Verelan®)
	100mg, 200 mg, 300 mg extended-release (Verelan® PM)
	180 mg, 240 mg extended-release tablets (Covera-HS®)
	IV: 2.5 mg/mL solution for injection
Special Notes	Many verapamil products are not equivalent on a mg:mg basis; monitor response and side effects when interchanging between products.
	Covera-HS and Verelan PM are chronotherapeutic products; give at bedtime to blunt
	early morning surge in blood pressure
Counseling	Take with food or milk to minimize gastric irritation
	Sustained-release tablets may be broken and each piece swallowed whole; do not chew or crush
	Extended-release tablets should be swallowed whole
	Contents of sustained-release capsules may be sprinkled on food (eg, apple sauce); do not chew or crush capsule contents

^{*}Refer to prescribing information for more complete information.

Sources

- 1. American College of Cardiology (ACC), American Heart Association (AHA), and the European Society of Cardiology (ESC). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Washington, DC: American College of Cardiology.
- 2. Heart Rhythm Society. AF360 Pocket Guide: Practical Rate and Rhythm Management of Atrial Fibrillation. 2010, Washington, DC: Heart Rhythm Society.
- 3. Tarascon Pocket Pharmacopoeia®2012.

[†]Dosages given in the table may differ from those recommended by the manufacturers.